Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Current Infectious Disease Reports
Erschienen in: Current Infectious Disease Reports 1/2010

01.01.2010

TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants

verfasst von: Sarah C. Higgins, Kingston H. G. Mills

Erschienen in: Current Infectious Disease Reports | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Vaccines based on attenuated or killed viruses and bacteria are highly effective in preventing infection with a range of pathogens, but can have safety issues. Therefore, a move is underway toward the development of subunit vaccines based on recombinant proteins or naked DNA. However, protein subunit vaccines are typically poorly immunogenic when administered alone and therefore require coadministration with adjuvants to boost the immune response. For many decades, very little progress was made in understanding the mechanism of action of adjuvants, but recently several significant breakthroughs have occurred in this area. The binding of pathogen-derived molecules to different immune sensors, including Toll-like receptors (TLR), nucleotide-binding oligomerization domain-like receptors (NLR), and retinoic acid–inducible gene (RIG)-1–like receptors (RLR), activates important innate immune pathways and provides not only an understanding of how current vaccines and adjuvants work, but also potential targets for novel adjuvant development.
Literatur
1.
Janeway CA Jr: Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989, 54(Pt 1):1-13.PubMed
2.
3.
Higgins SC, Jarnicki AG, Lavelle EC, Mills KH: TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17–producing T cells. J Immunol 2006, 177:7980–7989.PubMed
4.
Querec T, Bennouna S, Alkan S, et al.: Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006, 203:413–424.CrossRefPubMed
5.
6.
Condie RM, Zak SJ, Good RA: Effect of meningococcal endotoxin on the immune response. Proc Soc Exp Biol Med 1955, 90:355–360.PubMed
7.
Baldridge JR, Crane RT: Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 1999, 19:103–107.CrossRefPubMed
8.
Blander JM, Medzhitov R: Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440:808–812.CrossRefPubMed
9.
Bojang KA, Olodude F, Pinder M, et al.: Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 2005, 23:4148–4157.CrossRefPubMed
10.
Bovier PA, Farinelli T, Loutan L: Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. Vaccine 2005, 23:2424–2429.CrossRefPubMed
11.
Kaufmann SH: Tuberculosis and AIDS—a devilish liaison. Drug Discov Today 2007, 12(21–22):891–893.PubMed
12.
McCormack S, Tilzey A, Carmichael A, et al.: A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 2000, 18:1166–1177.CrossRefPubMed
13.
Verstraeten T, Descamps D, David MP, et al.: Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008, 26:6630–6638.CrossRefPubMed
14.
O’Hagan DT, De Gregorio E: The path to a successful vaccine adjuvant—‘the long and winding road.’ Drug Discov Today 2009, 14(11–12):541–551.CrossRefPubMed
15.
Baudner BC, Ronconi V, Casini D, et al.: MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res 2009, 26:1477–1485.CrossRefPubMed
16.
Dupuis M, Murphy TJ, Higgins D, et al.: Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 1998, 186:18–27.CrossRefPubMed
17.
Mosca F, Tritto E, Muzzi A, et al.: Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008, 105:10501–10506.CrossRefPubMed
18.
Ichinohe T, Tamura S, Kawaguchi A, et al.: Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 2007, 196:1313–1320.CrossRefPubMed
19.
Kumar H, Koyama S, Ishii KJ, et al.: Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J Immunol 2008, 180:683–687.PubMed
20.
Suhadolnik RJ, Reichenbach NL, Hitzges P, et al.: Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994, 18(Suppl 1):S96–S104.PubMed
21.
Bates JT, Honko AN, Graff AH, et al.: Mucosal adjuvant activity of flagellin in aged mice. Mech Ageing Dev 2008, 129:271–281.CrossRefPubMed
22.
Honko AN, Mizel SB: Mucosal administration of flagellin induces innate immunity in the mouse lung. Infect Immun 2004, 72:6676–6679.CrossRefPubMed
23.
McSorley SJ, Ehst BD, Yu Y, Gewirtz AT: Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol 2002, 169:3914–3919.PubMed
24.
Doring G, Meisner C, Stern M: A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A 2007, 104:11020–11025.CrossRefPubMed
25.
Heil F, Hemmi H, Hochrein H, et al.: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526–1529.CrossRefPubMed
26.
Gorden KB, Gorski KS, Gibson SJ, et al.: Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005, 174:1259–1268.PubMed
27.
Hemmi H, Kaisho T, Takeuchi O, et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002, 3:196–200.CrossRefPubMed
28.
Klinman DM, Xie H, Little SF, et al.: CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 2004, 22(21–22):2881–2886.CrossRefPubMed
29.
Schmidt C: Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 2007, 25:825–826.CrossRefPubMed
30.
Schubert C: Boosting our best shot. Nat Med 2009, 15:984–988.
31.
Conroy H, Marshall NA, Mills KH: TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 2008, 27:168–180.CrossRefPubMed
32.
• Jarnicki AG, Conroy H, Brereton C, et al.: Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008, 180:3797–3806. This article illustrates the limitations of TLR agonists as adjuvants and how they can be made more effective by modulating downstream signaling pathways.
33.
Gavin AL, Hoebe K, Duong B, et al.: Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006, 314:1936–1938.CrossRefPubMed
34.
Lopez CB, Moltedo B, Alexopoulou L, et al.: TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J Immunol 2004, 173:6882–6889.PubMed
35.
Sanders CJ, Franchi L, Yarovinsky F, et al.: Induction of adaptive immunity by flagellin does not require robust activation of innate immunity. Eur J Immunol 2009, 39:359–371.CrossRefPubMed
36.
Miao EA, Alpuche-Aranda CM, Dors M, et al.: Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 2006, 7:569–575.CrossRefPubMed
37.
Kato H, Sato S, Yoneyama M, et al.: Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005, 23:19–28.CrossRefPubMed
38.
Kawai T, Takahashi K, Sato S, et al.: IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005, 6:981–988.CrossRefPubMed
39.
• Kobiyama K, Takeshita F, Ishii KJ, et al.: A signaling polypeptide derived from an innate immune adaptor molecule can be harnessed as a new class of vaccine adjuvant. J Immunol 2009, 182:1593–1601. These authors showed that a polypeptide corresponding to an intracellular signaling molecule in the RIG-1 pathway could enhanced immune responses in vivo and therefore had potential as an adjuvant.
40.
Adam A, Ciorbaru R, Petit JF, Lederer E: Isolation and properties of a macromolecular, water-soluble, immuno-adjuvant fraction from the cell wall of Mycobacterium smegmatis. Proc Natl Acad Sci U S A 1972, 69:851–854.CrossRefPubMed
41.
Magalhaes JG, Fritz JH, Le Bourhis L, et al.: Nod2-dependent Th2 polarization of antigen-specific immunity. J Immunol 2008, 181:7925–7935.PubMed
42.
Keitel W, Couch R, Bond N, et al.: Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 1993, 11:909–913.CrossRefPubMed
43.
Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G: The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009, 10:241–247.CrossRefPubMed
44.
Staruch MJ, Wood DD: The adjuvanticity of interleukin 1 in vivo. J Immunol 1983, 130:2191–2194.PubMed
45.
Kanneganti TD, Body-Malapel M, Amer A, et al.: Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 2006, 281:36560–36568.CrossRefPubMed
46.
Martinon F, Tschopp J: Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007, 14:10–22.CrossRefPubMed
47.
Akaike T, Ando M, Oda T, et al.: Dependence on O2-generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J Clin Invest 1990, 85:739–745.CrossRefPubMed
48.
Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516–521.CrossRefPubMed
49.
Hornung V, Bauernfeind F, Halle A, et al.: Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008, 9:847–856.CrossRefPubMed
50.
• Eisenbarth SC, Colegio OR, O’Connor W, et al.: Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122–1126. This article provided the first evidence that the mechanism of action of alum may be mediated through activation of innate immunity (Editor: make this two star reference).
51.
Kool M, Petrilli V, De Smedt T, et al.: Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008, 181:3755–3759.PubMed
52.
Li H, Willingham SB, Ting JP, Re F: Cutting edge: inflammasome activation by alum and alum’s adjuvant effect are mediated by NLRP3. J Immunol 2008, 181:17–21.PubMed
53.
• Sharp FA, Ruane D, Claass B, et al.: Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 2009, 106:870–875. This article shows that biodegradable microparticles have adjuvant as well as vaccine delivery properties, and that this activity is mediated through activation of the inflammasome.
54.
Geijtenbeek TB, Gringhuis SI: Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009, 9:465–479.CrossRefPubMed
55.
Werninghaus K, Babiak A, Gross O, et al.: Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med 2009, 206:89–97.CrossRefPubMed
56.
Geisel RE, Sakamoto K, Russell DG, Rhoades ER: In vivo activity of released cell wall lipids of Mycobacterium bovis bacillus Calmette-Guerin is due principally to trehalose mycolates. J Immunol 2005, 174, 5007–5015.PubMed
57.
Khader SA, Bell GK, Pearl JE, et al.: IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369–377.CrossRefPubMed
58.
Lima KM, Santos SA, Lima VM, et al.: Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis. Gene Ther 2003, 10:678–685.CrossRefPubMed
59.
Davidsen J, Rosenkrands I, Christensen D, et al.: Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005, 1718(1–2):22–31.PubMed
60.
Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P: Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 2004, 72:1608–1617.CrossRefPubMed
61.
LeibundGut-Landmann S, Gross O, Robinson MJ, et al.: Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007, 8:630–638.CrossRefPubMed
62.
Napolitani G, Rinaldi A, Bertoni F, et al.: Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005, 6:769–776.CrossRefPubMed
63.
Fritz JH, Girardin SE, Fitting C, et al.: Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol 2005, 35:2459–2470.CrossRefPubMed
Metadaten
Titel
TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants
verfasst von
Sarah C. Higgins
Kingston H. G. Mills
Publikationsdatum
01.01.2010
Verlag
Current Science Inc.
Erschienen in
Current Infectious Disease Reports / Ausgabe 1/2010
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-009-0080-9

Weitere Artikel der Ausgabe 1/2010

Current Infectious Disease Reports 1/2010 Zur Ausgabe

Clinical Trial Report

Antimicrobial Therapy of Otitis Media Reduces the Incidence of Mastoiditis

OriginalPaper

Drug-Resistant Tuberculosis in Sub-Saharan Africa

OriginalPaper

The Role of Antibiotics in the Management of Patients with Acute Necrotizing Pancreatitis

OriginalPaper

Advances in the Development of Microbicides for the Prevention of HIV Infection

OriginalPaper

Non–AIDS-Defining Malignancies in Patients with HIV in the HAART Era

OriginalPaper

The HIV-Infected Adolescent

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise